Cabio Biotech Wuhan Co Ltd (688089) - Total Liabilities
Based on the latest financial reports, Cabio Biotech Wuhan Co Ltd (688089) has total liabilities worth CN¥183.42 Million CNY (≈ $26.84 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash efficiency ratio of Cabio Biotech Wuhan Co Ltd to assess how effectively this company generates cash.
Cabio Biotech Wuhan Co Ltd - Total Liabilities Trend (2013–2024)
This chart illustrates how Cabio Biotech Wuhan Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check Cabio Biotech Wuhan Co Ltd (688089) asset resilience to evaluate the company's liquid asset resilience ratio.
Cabio Biotech Wuhan Co Ltd Competitors by Total Liabilities
The table below lists competitors of Cabio Biotech Wuhan Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Yangzhou Chenhua New Material Co Ltd
SHE:300610
|
China | CN¥449.53 Million |
|
Vox Royalty Corp.
TO:VOXR
|
Canada | CA$22.24 Million |
|
Miwon Specialty Chemical Co Ltd
KO:268280
|
Korea | ₩106.74 Billion |
|
VT Industrial Technology Co Ltd
SHE:300707
|
China | CN¥740.87 Million |
|
IndoStar Capital Finance Limited
NSE:INDOSTAR
|
India | Rs55.85 Billion |
|
Cadiz Inc
NASDAQ:CDZI
|
USA | $100.27 Million |
|
Lootom Telcovideo Network Wuxi Co Ltd
SHE:300555
|
China | CN¥70.69 Million |
|
Boss Energy Ltd
AU:BOE
|
Australia | AU$54.15 Million |
Liability Composition Analysis (2013–2024)
This chart breaks down Cabio Biotech Wuhan Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Cabio Biotech Wuhan Co Ltd worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.79 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cabio Biotech Wuhan Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cabio Biotech Wuhan Co Ltd (2013–2024)
The table below shows the annual total liabilities of Cabio Biotech Wuhan Co Ltd from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥117.27 Million ≈ $17.16 Million |
-0.28% |
| 2023-12-31 | CN¥117.60 Million ≈ $17.21 Million |
-36.69% |
| 2022-12-31 | CN¥185.77 Million ≈ $27.18 Million |
+178.61% |
| 2021-12-31 | CN¥66.68 Million ≈ $9.76 Million |
+12.44% |
| 2020-12-31 | CN¥59.30 Million ≈ $8.68 Million |
+22.89% |
| 2019-12-31 | CN¥48.26 Million ≈ $7.06 Million |
-12.25% |
| 2018-12-31 | CN¥54.99 Million ≈ $8.05 Million |
+31.01% |
| 2017-12-31 | CN¥41.98 Million ≈ $6.14 Million |
-43.41% |
| 2016-12-31 | CN¥74.17 Million ≈ $10.85 Million |
-13.35% |
| 2015-12-31 | CN¥85.60 Million ≈ $12.53 Million |
+106.19% |
| 2014-12-31 | CN¥41.52 Million ≈ $6.08 Million |
+4.62% |
| 2013-12-31 | CN¥39.68 Million ≈ $5.81 Million |
-- |
About Cabio Biotech Wuhan Co Ltd
Cabio Biotech (Wuhan) Co., Ltd. develops, produces, and markets arachidonic and docosahexaenoic acids, and beta-carotene for domestic and foreign infant formula, and healthy food manufacturers. It offers human and animal nutrition, personal care, and synthetic biology products. The company was founded in 1999 and is based in Wuhan, the People's Republic of China.